Literature DB >> 18703565

Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide.

Manel Puig-Domingo1, Gonzalo Díaz, Joanna Nicolau, Cristián Fernández, Sergio Rueda, Irene Halperin.   

Abstract

OBJECTIVE: Hypoparathyroidism is usually controlled with calcium and vitamin-D supplements; in very few cases this treatment fails and teriparatide may be an alternative. We report the first case of hypoparathyroidism refractory to vitamin-D therapy requiring multipulse teriparatide treatment. CASE REPORT: A 53 year-old woman presented severe hypocalcemia and hypomagnesemia after thyroidectomy. Preoperatively, mild hypercalciuria was detected with parathyroid hormone (PTH) 69 pg/ml (normal 10-45) and 25-OH-vitamin D 9 ng/ml (normal 20-40) and normal levels of magnesium. No response was seen with oral and i.v. calcium and magnesium, or even with 5 microg calcitriol/day, suggesting a vitamin-D resistance status. Calcium sensor and vitamin-D receptor gene mutation studies were negative. INTERVENTIONS AND
RESULTS: The following treatments were tried: i) s.c. recombinant human PTH (rhPTH) 1-34 plus oral calcitriol, calcium, and magnesium, was partially effective, but symptoms resumed 4 h after the injection of 20 microg rhPTH; stable calcemia was not achieved even with 4-6 injections/day of teriparatide; ii) two trials of heterologous parathyroid transplant were performed but rejection was detected 3 months after; iii) i.v. magnesium decreased rhPTH requirements but i.m. administration was not tolerated and iv) multipulse s.c. infusion of teriparatide achieved complete normalization of serum calcium, phosphate, magnesium, calciuria and magnesuria with relatively low rhPTH doses (25-35 microg/day) for more than a year.
CONCLUSIONS: Vitamin-D unresponsiveness leads to uncontrolled hypocalcemia when postsurgical hypoparathyroidism occurs; in situations of no response to usual or higher doses of vitamin-D and s.c. injections of rhPTH, treatment with teriparatide multipulse s.c. infusor is an effective and safe alternative.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18703565     DOI: 10.1530/EJE-08-0269

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  11 in total

Review 1.  Impact of recombinant PTH on management of hypoparathyroidism: a systematic review.

Authors:  Y Ramakrishnan; H C Cocks
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-01-08       Impact factor: 2.503

2.  Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism.

Authors:  Karen K Winer; Bo Zhang; Joseph A Shrader; Donna Peterson; Michaele Smith; Paul S Albert; Gordon B Cutler
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

Review 3.  Mini-review: pump therapy in endocrinology & metabolism beyond diabetes.

Authors:  Burçak Cavnar Helvacı; Hüsniye Başer; Bekir Çakır
Journal:  Endocrine       Date:  2022-02-15       Impact factor: 3.633

Review 4.  Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism.

Authors:  Karine Aouchiche; Rachel Reynaud; Vincent Amodru; Thierry Brue; Thomas Cuny
Journal:  Endocrine       Date:  2022-01-04       Impact factor: 3.925

Review 5.  Management of Hypoparathyroidism: Present and Future.

Authors:  John P Bilezikian; Maria Luisa Brandi; Natalie E Cusano; Michael Mannstadt; Lars Rejnmark; René Rizzoli; Mishaela R Rubin; Karen K Winer; Uri A Liberman; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2016-03-03       Impact factor: 5.958

6.  Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism.

Authors:  Karen K Winer; Kara A Fulton; Paul S Albert; Gordon B Cutler
Journal:  J Pediatr       Date:  2014-06-16       Impact factor: 4.406

7.  Teriparatide - Indications beyond osteoporosis.

Authors:  Marilyn Lee Cheng; Vishal Gupta
Journal:  Indian J Endocrinol Metab       Date:  2012-05

8.  Continuous rhPTH (1-34) treatment in chronic hypoparathyroidism.

Authors:  Carmina Teresa Fuss; Stephanie Burger-Stritt; Silke Horn; Ann-Cathrin Koschker; Kathrin Frey; Almuth Meyer; Stefanie Hahner
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-05-29

Review 9.  Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus.

Authors:  Aliya A Khan; Christian A Koch; Stan Van Uum; Jean Patrice Baillargeon; Jens Bollerslev; Maria Luisa Brandi; Claudio Marcocci; Lars Rejnmark; Rene Rizzoli; M Zakarea Shrayyef; Rajesh Thakker; Bulent O Yildiz; Bart Clarke
Journal:  Eur J Endocrinol       Date:  2019-03       Impact factor: 6.664

10.  Post-Operative Permanent Hypoparathyroidism and Preoperative Vitamin D Prophylaxis.

Authors:  Tara Kannan; Yasmin Foster; David J Ho; Scott J Gelzinnis; Michael Merakis; Zsolt J Balogh; Katie Wynne; Cino Bendinelli
Journal:  J Clin Med       Date:  2021-01-24       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.